Corporate Announcement 14.03.2020

  Dear Customer, Like many of you we have been closely following the developments about coronavirus. At Medichem we deeply care about our ...


Q4’19 – Latest Authorizations by the Regulatory Agencies – Asia

  Medichem receives the Approval Notice Letter by the Korean Authorities for Apixaban´s Active Pharmaceutical Ingredient – Q4’19 Mediche...


Medichem Cares, Sustainable Environment

Sustainable Environment by Medichem


Medichem’s R&D and Business Development summit in ESADECREAPOLIS

What could be more inspiring than the ESADECREAPOLIS meeting rooms for Medichem's R&D and Business Development summit? On July 9th and 10th,...


USP’s Donor Recognition Program would like to recognize Medichem for its contributions…

  "USP’s Donor Recognition Program would like to recognize Medichem for its contributions during the 2018 calendar year" Says Ronald T. Pie...


“Fostering The Culture of Innovation and Excellence”

  On June 26th, Medichem participated in a Design Thinking Workshop organized by Ship2B. In line with Medichem´s Culture of Innovation, th...


We are proud to announce that Medichem´s Rivaroxaban 2.5mg, 10mg, 15mg and 20 mg DCP has been approved! … And API Rivaroxaban EU and US DMFs have been successfully filed!


First European APIs, Sugammadex and Apixaban, filed to the NMPA!